Reviewed By
Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 28 Researches
7.7
USERS' SCORE
Good
Based on 4 Reviews
8.1
Supplement Facts
Serving Size: 1 Softgel
Amount Per Serving
%DV
Calories
10
Total Fat
1 g
1%*
Polyunsaturated Fat
1 g
†
Fish Oil Concentrate
1 g (1,000 mg)
†
Docosahexaenoic Acid (DHA)
500 mg
†
Eicosapentaenoic Acid (EPA)
250 mg
†
Top Medical Research Studies
9
We investigated the potential of DHA-enriched phosphatidylserine (DHA-PS) in addressing liver injuries caused by cyclophosphamide in mice. By administering cyclophosphamide over five days, we created a model to simulate this liver damage. Following this, we treated the mice with different doses of DHA-PS for a week to see if it could help heal their livers.
Our findings were quite promising. The mice receiving DHA-PS experienced significant improvements in key liver health indicators, including reduced inflammation and oxidative stress. Through advanced analysis, we discovered that DHA-PS helped correct metabolic imbalances caused by cyclophosphamide, which is a crucial aspect of liver recovery.
Additionally, we observed that DHA-PS has a positive impact on the gut-liver axis. This treatment restored the intestinal barrier, reduced harmful compounds in the bloodstream, and improved overall gut microbiota health. By balancing the gut bacteria, we enhanced the overall health of the mice.
Overall, the results suggest that DHA-PS could be a valuable therapeutic option or functional food for combating liver injuries related to cyclophosphamide. This study highlights the potential benefits of DHA on liver health and underscores the importance of the gut-liver connection.
Our findings were quite promising. The mice receiving DHA-PS experienced significant improvements in key liver health indicators, including reduced inflammation and oxidative stress. Through advanced analysis, we discovered that DHA-PS helped correct metabolic imbalances caused by cyclophosphamide, which is a crucial aspect of liver recovery.
Additionally, we observed that DHA-PS has a positive impact on the gut-liver axis. This treatment restored the intestinal barrier, reduced harmful compounds in the bloodstream, and improved overall gut microbiota health. By balancing the gut bacteria, we enhanced the overall health of the mice.
Overall, the results suggest that DHA-PS could be a valuable therapeutic option or functional food for combating liver injuries related to cyclophosphamide. This study highlights the potential benefits of DHA on liver health and underscores the importance of the gut-liver connection.
Read More
9
We explored the impact of docosahexaenoic acid (DHA), a type of omega-3 fatty acid, on the health of our liver, especially regarding nonalcoholic fatty liver disease (NAFLD). Using a zebrafish model with a specific mutation that prevents the production of DHA, we aimed to understand how this absence affects liver lipid balance and overall liver health.
Our findings revealed that without sufficient DHA, the liver showed increased fat storage and issues with fat processing. Instead of breaking down fats as it should, the liver was overwhelmed with lipids, leading to the telltale signs of NAFLD. Additionally, we noted that the liver cells in our mutated model were suffering from structural damage and stress, primarily through a process known as ferroptosis—rather than the more commonly known apoptosis.
Interestingly, when we supplemented these fish with DHA through diet or genetic modifications, we observed a remarkable improvement in liver health. This suggests that maintaining proper levels of DHA is crucial for preventing fatty liver disease and protecting liver cells from damage.
Our findings revealed that without sufficient DHA, the liver showed increased fat storage and issues with fat processing. Instead of breaking down fats as it should, the liver was overwhelmed with lipids, leading to the telltale signs of NAFLD. Additionally, we noted that the liver cells in our mutated model were suffering from structural damage and stress, primarily through a process known as ferroptosis—rather than the more commonly known apoptosis.
Interestingly, when we supplemented these fish with DHA through diet or genetic modifications, we observed a remarkable improvement in liver health. This suggests that maintaining proper levels of DHA is crucial for preventing fatty liver disease and protecting liver cells from damage.
Read More
8
We explored how docosahexaenoic acid (DHA), a type of omega-3 fatty acid, affects liver function in individuals with obesity. The study involved patients with a body mass index (BMI) of 40 kg/m² or higher. Half of these patients received a supplement of n-3 PUFAs, which included DHA, while the other half received a control treatment of butter.
After eight weeks, liver biopsies were taken and analyzed to see how gene expression was affected. The results showed that DHA treatment significantly influenced various pathways related to metabolism, immunity, and inflammation in the liver. Specifically, we observed that the treatment led to an upregulation of pathways involved in T-cell and B-cell functions, along with lipid metabolism. Interestingly, pathways related to glucagon signaling were downregulated.
Our findings offer valuable insights into DHA’s role in liver health, particularly in how it may help reduce inflammation and improve metabolic functions in obese individuals. This research sets the groundwork for future studies that could further explore the benefits of omega-3 fatty acids for liver disease.
After eight weeks, liver biopsies were taken and analyzed to see how gene expression was affected. The results showed that DHA treatment significantly influenced various pathways related to metabolism, immunity, and inflammation in the liver. Specifically, we observed that the treatment led to an upregulation of pathways involved in T-cell and B-cell functions, along with lipid metabolism. Interestingly, pathways related to glucagon signaling were downregulated.
Our findings offer valuable insights into DHA’s role in liver health, particularly in how it may help reduce inflammation and improve metabolic functions in obese individuals. This research sets the groundwork for future studies that could further explore the benefits of omega-3 fatty acids for liver disease.
Read More
Most Useful Reviews
7.5
Improves liver health
DHA food supplement with excellent quality. It contains Omega 3 fish oil, DHA (500 mg per capsule), and EPA (250 mg). The capsules are medium-sized, odourless, and sealed. I have noticed improvements in my health, including reduced risk of liver disease, coronary heart disease, stroke, and enhanced brain activity. I take one capsule once or twice daily with meals, and it has also improved my hair structure.
Read More
7.5
Supports liver protection
High-quality ingredients with no fishy taste and a high omega-3 DHA content. This supplement reduces inflammation and protects the liver, heart, and hair while also lowering cholesterol as we age. All these benefits are packed into one product.
Read More
7.5
Prevents liver illness
I have consistently taken omega-3s for years and believe people who don’t eat much fish should include them in their diet. DHA and EPA fatty acids are essential for metabolism, inflammation protection, and vascular health. I take this complex to benefit from its powerful anti-ageing properties, especially for brain health. The capsules are easy to swallow, odourless, and reasonably priced.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 28 Researches
7.7
- All Researches
9
We explored the effects of docosahexaenoic acid (DHA) on liver disease, specifically looking at its role in nonalcoholic fatty liver disease (NAFLD) and its potential connection to Alzheimer's disease. Our study conducted on APP/PS1 mice involved four groups of animals fed different diets—one with DHA, one with medium-chain triglycerides (MCTs), and one that combined both treatments.
Throughout the study, which lasted eight months, we observed a significant reduction in blood and liver lipids in the group that received both DHA and MCTs. This combination not only alleviated signs of NAFLD but also reduced the buildup of amyloid-β (Aβ), a protein linked to Alzheimer's, in the brain and serum.
Additionally, our findings indicated that DHA combined with MCTs improved the activity of liver enzymes critical for lipid metabolism. This suggests that these compounds together may enhance the liver's ability to clear fat and cholesterol while also increasing Aβ clearance.
While we noted the benefits of DHA, it's important to remember that the effects we observed were influenced by the combination with MCTs, making it challenging to pinpoint DHA's isolated impact. Still, our research provides valuable insight into how enhancing dietary fats could support liver health and potentially mitigate connections to neurodegenerative diseases.
Throughout the study, which lasted eight months, we observed a significant reduction in blood and liver lipids in the group that received both DHA and MCTs. This combination not only alleviated signs of NAFLD but also reduced the buildup of amyloid-β (Aβ), a protein linked to Alzheimer's, in the brain and serum.
Additionally, our findings indicated that DHA combined with MCTs improved the activity of liver enzymes critical for lipid metabolism. This suggests that these compounds together may enhance the liver's ability to clear fat and cholesterol while also increasing Aβ clearance.
While we noted the benefits of DHA, it's important to remember that the effects we observed were influenced by the combination with MCTs, making it challenging to pinpoint DHA's isolated impact. Still, our research provides valuable insight into how enhancing dietary fats could support liver health and potentially mitigate connections to neurodegenerative diseases.
Read More
9
We explored the effectiveness of docosahexaenoic acid (DHA), particularly when delivered via nanoparticles, in treating liver disease, specifically hepatocellular carcinoma (HCC), in three rodent models. Our focus was on understanding how DHA affects HCC lesions as well as the performance of weighted amide proton transfer (APT) MRI as a monitoring tool.
In all three models—diethylnitrosamine (DEN) induced HCC, N1S1 syngeneic orthotopic xenograft, and human HepG2 ectopic xenograft—the APT MRI revealed higher signals from the cancerous tissue compared to surrounding normal tissue. Notably, in the DEN model, we found that the APT signal could effectively differentiate between malignant lesions and benign nodules.
After administering LDL-DHA nanoparticles directly into tumors, we observed a rapid decrease in APT signals within 72 hours, suggesting a promising therapeutic response. This trend was consistent in both N1S1 and HepG2 xenografts, indicating that DHA's effects, accelerated by nanoparticles, hold potential for therapeutic applications in liver cancer management.
Overall, our findings underscore the utility of APT imaging in the diagnostic and therapeutic landscapes of HCC, showcasing how innovative delivery methods can enhance treatment outcomes.
In all three models—diethylnitrosamine (DEN) induced HCC, N1S1 syngeneic orthotopic xenograft, and human HepG2 ectopic xenograft—the APT MRI revealed higher signals from the cancerous tissue compared to surrounding normal tissue. Notably, in the DEN model, we found that the APT signal could effectively differentiate between malignant lesions and benign nodules.
After administering LDL-DHA nanoparticles directly into tumors, we observed a rapid decrease in APT signals within 72 hours, suggesting a promising therapeutic response. This trend was consistent in both N1S1 and HepG2 xenografts, indicating that DHA's effects, accelerated by nanoparticles, hold potential for therapeutic applications in liver cancer management.
Overall, our findings underscore the utility of APT imaging in the diagnostic and therapeutic landscapes of HCC, showcasing how innovative delivery methods can enhance treatment outcomes.
Read More
9
Nutrient cocktail improves liver health
We conducted a study to understand how a specific mix of nutrients, including docosahexaenoic acid, impacts liver health in adults suffering from metabolic dysfunction-associated steatotic liver disease (MASLD) due to obesity. This involved a carefully controlled pilot clinical trial where participants were either given a nutrient cocktail or a placebo over three months.
The results were quite promising. Those who received the nutrient cocktail had notable reductions in liver fat content and fibrosis as indicated by improvements in their liver scans. Specifically, we observed an average reduction of 4% in the controlled attenuation parameter (CAP) and 7.8% in transient elastography (TE) scores among the treatment group.
Although docosahexaenoic acid was part of this nutrient blend, the study didn't isolate its effects. Therefore, while the overall findings suggest that such a supplementation might enhance liver health, the individual contribution of docosahexaenoic acid remains unclear. This points towards a need for more targeted research to fully understand its role in treating liver conditions.
The results were quite promising. Those who received the nutrient cocktail had notable reductions in liver fat content and fibrosis as indicated by improvements in their liver scans. Specifically, we observed an average reduction of 4% in the controlled attenuation parameter (CAP) and 7.8% in transient elastography (TE) scores among the treatment group.
Although docosahexaenoic acid was part of this nutrient blend, the study didn't isolate its effects. Therefore, while the overall findings suggest that such a supplementation might enhance liver health, the individual contribution of docosahexaenoic acid remains unclear. This points towards a need for more targeted research to fully understand its role in treating liver conditions.
Read More
9
We investigated the potential of DHA-enriched phosphatidylserine (DHA-PS) in addressing liver injuries caused by cyclophosphamide in mice. By administering cyclophosphamide over five days, we created a model to simulate this liver damage. Following this, we treated the mice with different doses of DHA-PS for a week to see if it could help heal their livers.
Our findings were quite promising. The mice receiving DHA-PS experienced significant improvements in key liver health indicators, including reduced inflammation and oxidative stress. Through advanced analysis, we discovered that DHA-PS helped correct metabolic imbalances caused by cyclophosphamide, which is a crucial aspect of liver recovery.
Additionally, we observed that DHA-PS has a positive impact on the gut-liver axis. This treatment restored the intestinal barrier, reduced harmful compounds in the bloodstream, and improved overall gut microbiota health. By balancing the gut bacteria, we enhanced the overall health of the mice.
Overall, the results suggest that DHA-PS could be a valuable therapeutic option or functional food for combating liver injuries related to cyclophosphamide. This study highlights the potential benefits of DHA on liver health and underscores the importance of the gut-liver connection.
Our findings were quite promising. The mice receiving DHA-PS experienced significant improvements in key liver health indicators, including reduced inflammation and oxidative stress. Through advanced analysis, we discovered that DHA-PS helped correct metabolic imbalances caused by cyclophosphamide, which is a crucial aspect of liver recovery.
Additionally, we observed that DHA-PS has a positive impact on the gut-liver axis. This treatment restored the intestinal barrier, reduced harmful compounds in the bloodstream, and improved overall gut microbiota health. By balancing the gut bacteria, we enhanced the overall health of the mice.
Overall, the results suggest that DHA-PS could be a valuable therapeutic option or functional food for combating liver injuries related to cyclophosphamide. This study highlights the potential benefits of DHA on liver health and underscores the importance of the gut-liver connection.
Read More
9
Liposomal DHA alters liver fats
We investigated how various dietary liposomal complexes featuring docosahexaenoic acid (DHA) influence liver health. The study used F1 (C57blxDBA2\6) mice over a 3-month period, looking at changes in liver phospholipids due to different diets.
The mice were divided into groups, some receiving a liposomal complex with important ingredients like phosphatidylcholine and fish oil. We found that the mice consuming the PC-CEO-FO-SC liposomal complex saw a significant increase in n-3 fatty acids, particularly DHA, in their liver phospholipids.
This increase in DHA was also linked to a decrease in n-6 fatty acids, such as arachidonic acid. As a result, the ratio between n-6 and n-3 fatty acids improved, which is promising for reducing inflammation and potentially decreasing the risk of chronic diseases related to the liver.
However, while these findings are encouraging, they don't directly isolate DHA's effect specifically on liver disease, so it’s important to interpret the results with caution.
The mice were divided into groups, some receiving a liposomal complex with important ingredients like phosphatidylcholine and fish oil. We found that the mice consuming the PC-CEO-FO-SC liposomal complex saw a significant increase in n-3 fatty acids, particularly DHA, in their liver phospholipids.
This increase in DHA was also linked to a decrease in n-6 fatty acids, such as arachidonic acid. As a result, the ratio between n-6 and n-3 fatty acids improved, which is promising for reducing inflammation and potentially decreasing the risk of chronic diseases related to the liver.
However, while these findings are encouraging, they don't directly isolate DHA's effect specifically on liver disease, so it’s important to interpret the results with caution.
Read More
User Reviews
USERS' SCORE
Good
Based on 4 Reviews
8.1
- All Reviews
- Positive Reviews
- Negative Reviews
7.5
Improves liver health
DHA food supplement with excellent quality. It contains Omega 3 fish oil, DHA (500 mg per capsule), and EPA (250 mg). The capsules are medium-sized, odourless, and sealed. I have noticed improvements in my health, including reduced risk of liver disease, coronary heart disease, stroke, and enhanced brain activity. I take one capsule once or twice daily with meals, and it has also improved my hair structure.
Read More
7.5
Supports liver protection
High-quality ingredients with no fishy taste and a high omega-3 DHA content. This supplement reduces inflammation and protects the liver, heart, and hair while also lowering cholesterol as we age. All these benefits are packed into one product.
Read More
7.5
Prevents liver illness
I have consistently taken omega-3s for years and believe people who don’t eat much fish should include them in their diet. DHA and EPA fatty acids are essential for metabolism, inflammation protection, and vascular health. I take this complex to benefit from its powerful anti-ageing properties, especially for brain health. The capsules are easy to swallow, odourless, and reasonably priced.
Read More
6
Reduces liver disease
A good quality product with a high DHA dosage, though the capsules are large due to the concentration. They are easy to swallow, with no smell or aftertaste. Omega-3 fatty acids are crucial for our cells, serving as building material and providing anti-inflammatory effects, which are vital in treating liver disease and other serious health conditions.
Read More
Frequently Asked Questions
7.5
Improves liver health
DHA food supplement with excellent quality. It contains Omega 3 fish oil, DHA (500 mg per capsule), and EPA (250 mg). The capsules are medium-sized, odourless, and sealed. I have noticed improvements in my health, including reduced risk of liver disease, coronary heart disease, stroke, and enhanced brain activity. I take one capsule once or twice daily with meals, and it has also improved my hair structure.
6
Reduces liver disease
A good quality product with a high DHA dosage, though the capsules are large due to the concentration. They are easy to swallow, with no smell or aftertaste. Omega-3 fatty acids are crucial for our cells, serving as building material and providing anti-inflammatory effects, which are vital in treating liver disease and other serious health conditions.
7.5
Supports liver protection
High-quality ingredients with no fishy taste and a high omega-3 DHA content. This supplement reduces inflammation and protects the liver, heart, and hair while also lowering cholesterol as we age. All these benefits are packed into one product.
7.5
Prevents liver illness
I have consistently taken omega-3s for years and believe people who don’t eat much fish should include them in their diet. DHA and EPA fatty acids are essential for metabolism, inflammation protection, and vascular health. I take this complex to benefit from its powerful anti-ageing properties, especially for brain health. The capsules are easy to swallow, odourless, and reasonably priced.
9
We explored the effects of docosahexaenoic acid (DHA) on liver disease, specifically looking at its role in nonalcoholic fatty liver disease (NAFLD) and its potential connection to Alzheimer's disease. Our study conducted on APP/PS1 mice involved four groups of animals fed different diets—one with DHA, one with medium-chain triglycerides (MCTs), and one that combined both treatments.
Throughout the study, which lasted eight months, we observed a significant reduction in blood and liver lipids in the group that received both DHA and MCTs. This combination not only alleviated signs of NAFLD but also reduced the buildup of amyloid-β (Aβ), a protein linked to Alzheimer's, in the brain and serum.
Additionally, our findings indicated that DHA combined with MCTs improved the activity of liver enzymes critical for lipid metabolism. This suggests that these compounds together may enhance the liver's ability to clear fat and cholesterol while also increasing Aβ clearance.
While we noted the benefits of DHA, it's important to remember that the effects we observed were influenced by the combination with MCTs, making it challenging to pinpoint DHA's isolated impact. Still, our research provides valuable insight into how enhancing dietary fats could support liver health and potentially mitigate connections to neurodegenerative diseases.
Throughout the study, which lasted eight months, we observed a significant reduction in blood and liver lipids in the group that received both DHA and MCTs. This combination not only alleviated signs of NAFLD but also reduced the buildup of amyloid-β (Aβ), a protein linked to Alzheimer's, in the brain and serum.
Additionally, our findings indicated that DHA combined with MCTs improved the activity of liver enzymes critical for lipid metabolism. This suggests that these compounds together may enhance the liver's ability to clear fat and cholesterol while also increasing Aβ clearance.
While we noted the benefits of DHA, it's important to remember that the effects we observed were influenced by the combination with MCTs, making it challenging to pinpoint DHA's isolated impact. Still, our research provides valuable insight into how enhancing dietary fats could support liver health and potentially mitigate connections to neurodegenerative diseases.
9
We explored the effectiveness of docosahexaenoic acid (DHA), particularly when delivered via nanoparticles, in treating liver disease, specifically hepatocellular carcinoma (HCC), in three rodent models. Our focus was on understanding how DHA affects HCC lesions as well as the performance of weighted amide proton transfer (APT) MRI as a monitoring tool.
In all three models—diethylnitrosamine (DEN) induced HCC, N1S1 syngeneic orthotopic xenograft, and human HepG2 ectopic xenograft—the APT MRI revealed higher signals from the cancerous tissue compared to surrounding normal tissue. Notably, in the DEN model, we found that the APT signal could effectively differentiate between malignant lesions and benign nodules.
After administering LDL-DHA nanoparticles directly into tumors, we observed a rapid decrease in APT signals within 72 hours, suggesting a promising therapeutic response. This trend was consistent in both N1S1 and HepG2 xenografts, indicating that DHA's effects, accelerated by nanoparticles, hold potential for therapeutic applications in liver cancer management.
Overall, our findings underscore the utility of APT imaging in the diagnostic and therapeutic landscapes of HCC, showcasing how innovative delivery methods can enhance treatment outcomes.
In all three models—diethylnitrosamine (DEN) induced HCC, N1S1 syngeneic orthotopic xenograft, and human HepG2 ectopic xenograft—the APT MRI revealed higher signals from the cancerous tissue compared to surrounding normal tissue. Notably, in the DEN model, we found that the APT signal could effectively differentiate between malignant lesions and benign nodules.
After administering LDL-DHA nanoparticles directly into tumors, we observed a rapid decrease in APT signals within 72 hours, suggesting a promising therapeutic response. This trend was consistent in both N1S1 and HepG2 xenografts, indicating that DHA's effects, accelerated by nanoparticles, hold potential for therapeutic applications in liver cancer management.
Overall, our findings underscore the utility of APT imaging in the diagnostic and therapeutic landscapes of HCC, showcasing how innovative delivery methods can enhance treatment outcomes.
9
Nutrient cocktail improves liver health
We conducted a study to understand how a specific mix of nutrients, including docosahexaenoic acid, impacts liver health in adults suffering from metabolic dysfunction-associated steatotic liver disease (MASLD) due to obesity. This involved a carefully controlled pilot clinical trial where participants were either given a nutrient cocktail or a placebo over three months.
The results were quite promising. Those who received the nutrient cocktail had notable reductions in liver fat content and fibrosis as indicated by improvements in their liver scans. Specifically, we observed an average reduction of 4% in the controlled attenuation parameter (CAP) and 7.8% in transient elastography (TE) scores among the treatment group.
Although docosahexaenoic acid was part of this nutrient blend, the study didn't isolate its effects. Therefore, while the overall findings suggest that such a supplementation might enhance liver health, the individual contribution of docosahexaenoic acid remains unclear. This points towards a need for more targeted research to fully understand its role in treating liver conditions.
The results were quite promising. Those who received the nutrient cocktail had notable reductions in liver fat content and fibrosis as indicated by improvements in their liver scans. Specifically, we observed an average reduction of 4% in the controlled attenuation parameter (CAP) and 7.8% in transient elastography (TE) scores among the treatment group.
Although docosahexaenoic acid was part of this nutrient blend, the study didn't isolate its effects. Therefore, while the overall findings suggest that such a supplementation might enhance liver health, the individual contribution of docosahexaenoic acid remains unclear. This points towards a need for more targeted research to fully understand its role in treating liver conditions.
We conducted a study to explore how combining vitamin E with docosahexaenoic acid (DHA) might affect liver fat in adults suffering from Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). In this carefully designed trial, we randomized participants into four groups: one group received both vitamin E and DHA, while others received either vitamin E alone, DHA alone, or a placebo.
Over six months, we observed the effects of these treatments on liver fat content. Unfortunately, the results did not show any significant benefit from the combination of DHA and vitamin E in reducing liver fat when compared to the placebo group. Additionally, neither vitamin E nor DHA alone demonstrated any efficacy in lowering liver fat levels.
Despite our hopes, the study concluded that neither the combination nor the individual treatments effectively reduced liver fat or liver enzyme levels in the participants. This indicates that DHA, even when paired with vitamin E, may not be the solution we were looking for in managing MASLD.
Over six months, we observed the effects of these treatments on liver fat content. Unfortunately, the results did not show any significant benefit from the combination of DHA and vitamin E in reducing liver fat when compared to the placebo group. Additionally, neither vitamin E nor DHA alone demonstrated any efficacy in lowering liver fat levels.
Despite our hopes, the study concluded that neither the combination nor the individual treatments effectively reduced liver fat or liver enzyme levels in the participants. This indicates that DHA, even when paired with vitamin E, may not be the solution we were looking for in managing MASLD.
References
- Zhang Z, Zhou Q, Li Z, Huang F, Mo K, et al. DTX2 attenuates Lenvatinib-induced ferroptosis by suppressing docosahexaenoic acid biosynthesis through HSD17B4-dependent peroxisomal β-oxidation in hepatocellular carcinoma. Drug Resist Updat. 2025;81:101224. 10.1016/j.drup.2025.101224
- Zhang D, Wang Z, Wang X, Yue W, Zhang L, et al. Cosupplementation with DHA and medium-chain triglycerides ameliorates NAFLD and reduces amyloid-β accumulation by modulating hepatic lipid metabolism in APP/PS1 mice. Lipids. 2025. 10.1002/lipd.12436
- Wang X, Ishimatsu K, Li J, Wen X, Ou W, et al. APT imaging of hepatocellular carcinoma signals an effective therapeutic response in advance of tumor shrinkage. Hepat Oncol. 2024;11:2389031. 10.1080/20450923.2024.2389031
- Li J, Guo J, Yuen M, Yuen H, Peng Q. The comparative effects of ω-7 fatty acid-rich sea buckthorn oil and ω-3 fatty acid-rich DHA algal oil on improving high-fat diet-induced hyperlipidemia. Food Funct. 2025;16:1241. 10.1039/d4fo04961f
- Joerg R, Itariu BK, Amor M, Bilban M, Langer F, et al. The effect of long-chain n-3 PUFA on liver transcriptome in human obesity. Prostaglandins Leukot Essent Fatty Acids. 2024;204:102663. 10.1016/j.plefa.2024.102663
- Choi JH, Park SE, Kim S. Antarctic Krill Oil Supplementation Attenuates Hypercholesterolemia, Fatty Liver, and Oxidative Stress in Diet-Induced Obese Mice. Nutrients. 2024;16. 10.3390/nu16213614
- Zhang Y, Zhao Q, Zhao R, Lu Y, Jiang S, et al. Efficacy of DHA-enriched phosphatidylserine and its underlying mechanism in alleviating polystyrene nanoplastics-induced hepatotoxicity in mice. Int Immunopharmacol. 2024;142:113154. 10.1016/j.intimp.2024.113154
- Yang J, Félix-Soriano E, Martínez-Gayo A, Ibañez-Santos J, Sáinz N, et al. SIRT1 and FOXO1 role on MASLD risk: effects of DHA-rich n-3 PUFA supplementation and exercise in aged obese female mice and in post-menopausal overweight/obese women. J Physiol Biochem. 2024;80:697. 10.1007/s13105-024-01044-9
- Perva IT, Simina IE, Bende R, Motofelea AC, Chirita Emandi A, et al. Use of a Micronutrient Cocktail to Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Adults with Obesity: A Randomized, Double-Blinded Pilot Clinical Trial. Medicina (Kaunas). 2024;60. 10.3390/medicina60081366
- Zhang H, Lu Y, Zhang Y, Dong J, Jiang S, et al. DHA-enriched phosphatidylserine ameliorates cyclophosphamide-induced liver injury via regulating the gut-liver axis. Int Immunopharmacol. 2024;140:112895. 10.1016/j.intimp.2024.112895
- Guo C, Liu Z, Fan H, Wang H, Zhang X, et al. Nonlinear relationships of circulating polyunsaturated fatty acids with the complications of liver cirrhosis: A prospective, longitudinal cohort study. Clin Nutr. 2024;43:2083. 10.1016/j.clnu.2024.07.027
- Sabinari I, Horakova O, Cajka T, Kleinova V, Wieckowski MR, et al. Influence of Lipid Class Used for Omega-3 Fatty Acid Supplementation on Liver Fat Accumulation in MASLD. Physiol Res. 2024;73:S295.
- Alkhouri N, McCarthy D, Bayne AV, Blonquist T, Yurko-Mauro K, et al. The effect of vitamin E and docosahexaenoic acid ethyl ester on Metabolic Dysfunction-Associated steatotic Liver Disease (MASLD)-A randomised, double-blind, placebo-controlled, parallel-group clinical trial (PUVENAFLD). Aliment Pharmacol Ther. 2024;60:552. 10.1111/apt.18149
- Palmina N, Kononikhin A, Chagovets V, Tokareva A, Antipova A, et al. Dietary liposomal complexes change the fatty acid composition of hepatic bioactive phospholipids in F1(C57blxDBA2\6) mice, as shown by a lipidomic approach. Biomater Sci. 2024;12:3956. 10.1039/d4bm00431k
- Sotoudeheian M, Azarbad R, Mirahmadi SM. Investigating the correlation between polyunsaturated fatty acids intake and non-invasive biomarkers of liver fibrosis. Clin Nutr ESPEN. 2024;63:46. 10.1016/j.clnesp.2024.06.016
- Li X, Liu C, Zhang R, Li Y, Ye D, et al. Biosynthetic deficiency of docosahexaenoic acid causes nonalcoholic fatty liver disease and ferroptosis-mediated hepatocyte injury. J Biol Chem. 2024;300:107405. 10.1016/j.jbc.2024.107405
- Uthaiah NM, Venkataramareddy SR, Mudhol S, Sheikh AY. EPA-rich Nannochloropsis oceanica biomass regulates gut microbiota, alleviates inflammation and ameliorates liver fibrosis in rats. Food Res Int. 2025;202:115733. 10.1016/j.foodres.2025.115733
- MacLeod B, Wang C, Brown LH, Borkowski E, Nakamura MT, et al. Fads2 knockout mice reveal that ALA prevention of hepatic steatosis is dependent on delta-6 desaturase activity. J Lipid Res. 2024;65:100642. 10.1016/j.jlr.2024.100642
- Sumida W, Tainaka T, Shirota C, Makita S, Amano H, et al. Eicosapentaenoic acid administration ameliorates the progression of liver fibrosis after laparoscopic Kasai portoenterostomy. Pediatr Surg Int. 2024;40:239. 10.1007/s00383-024-05800-2
- Huang C, Yong Q, Lu Y, Wang L, Zheng Y, et al. Gentiopicroside improves non-alcoholic steatohepatitis by activating PPARα and suppressing HIF1. Front Pharmacol. 2024;15:1335814. 10.3389/fphar.2024.1335814
- Wang Y, Hou J, Li X, Chen P, Chen F, et al. Tyrosol regulates hepatic lipid metabolism in high-fat diet-induced NAFLD mice. Food Funct. 2024;15:3752. 10.1039/d3fo05345h
- Iizasa S, Nagao K, Tsuge K, Nagano Y, Yanagita T. Identification of genes regulated by lipids from seaweed Susabinori (Pyropia yezoensis) involved in the improvement of hepatic steatosis: Insights from RNA-Seq analysis in obese db/db mice. PLoS One. 2023;18:e0295591. 10.1371/journal.pone.0295591
- Hull MA, Ow PL, Ruddock S, Brend T, Smith AF, et al. Randomised, placebo-controlled, phase 3 trial of the effect of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver metastases: EPA for Metastasis Trial 2 (EMT2) study protocol. BMJ Open. 2023;13:e077427. 10.1136/bmjopen-2023-077427
- Videla LA, Valenzuela R, Del Campo A, Zúñiga-Hernández J. Omega-3 Lipid Mediators: Modulation of the M1/M2 Macrophage Phenotype and Its Protective Role in Chronic Liver Diseases. Int J Mol Sci. 2023;24. 10.3390/ijms242115528
- Chen YF, Fan ZK, Gao X, Zhou F, Guo XF, et al. n-3 polyunsaturated fatty acids in phospholipid or triacylglycerol form attenuate nonalcoholic fatty liver disease via mediating cannabinoid receptor 1/adiponectin/ceramide pathway. J Nutr Biochem. 2024;123:109484. 10.1016/j.jnutbio.2023.109484
- Liu W, Zhu M, Gong M, Zheng W, Zeng X, et al. Comparison of the Effects of Monounsaturated Fatty Acids and Polyunsaturated Fatty Acids on Liver Lipid Disorders in Obese Mice. Nutrients. 2023;15. 10.3390/nu15143200
- Rohwer N, Jelleschitz J, Höhn A, Weber D, Kühl AA, et al. Prevention of colitis-induced liver oxidative stress and inflammation in a transgenic mouse model with increased omega-3 polyunsaturated fatty acids. Redox Biol. 2023;64:102803. 10.1016/j.redox.2023.102803
- Roque-Jiménez JA, Oviedo-Ojeda MF, Whalin M, Lee-Rangel HA, Relling AE. Ewe early gestation supplementation with eicosapentaenoic and docosahexaenoic acids affects the liver, muscle, and adipose tissue fatty acid profile and liver mRNA expression in the offspring. J Anim Sci. 2023;101. 10.1093/jas/skad144
